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IL-1β, stimulated with IL-1β and Tendoactive® or pre-stimulated
with Tendoactive® followed by co-treatment with Tendoactive®
and IL-1β. Cell viability, adhesion, proliferation and the produc-
tion of ECM were analysed with light microscopy and transmis-
sion electron microscopy (TEM). Immunoﬂuorescence was used
to evaluate production of type I collagen, the main extracellu-
lar matrix protein produced by tenocytes. We also studied the
expression of the signal transduction and adhesion molecule β1-
integrin.Western Blotting (WB) was performed to evaluate the ex-
pression of apoptotic and inﬂammatory markers (metalloprotease-
1 (MMP-1), cyclooxygenase-2 (Cox-2) and caspase-3).
Results: Tendoactive® had a potent stimulatory effect on human
tenocyte proliferation and ECM production and was also able
to suppress the catabolic, apoptotic and inﬂammatory effects
induced by IL-1β in human tenocytes. This was demonstrated by
the suppression of IL-1β-induced expression of MMP-1, Cox-2 and
caspase-3 and up-regulation of type I collagen and β1-integrin.
Conclusions: The results presented suggest that this formulation
inhibits catabolic and inﬂammatory processes in an in vitro model
of tendonitis.Tendoactive® may therefore be used on prophylaxis
and treatment of tendinopathies to stimulate tendon healing, re-
generation and repair.
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EFFECTIVENESS OF TREATMENT OF TENDINITIS AND
PLANTAR FASCIITIS BY TENDOACTIVE™
F. Nadal1, T. Bové2, D. Sanchís3, D. Martinez-Puig4
1Clínica Sagrada Família, Barcelona, Spain; 2Futbol Club
Barcelona, Barcelona, Spain; 3Ctr. de Fisioteràpia Toni Bové,
Barcelona, Spain; 4Bioiberica S.A., Palafolls, Spain
Purpose: To evaluate the effectiveness of Tendoactive™ adminis-
tration in the treatment of 3 different tendinopathies, such as epi-
condylitis, supraspinous tendinopathy, achilles tendinopathy and
plantar fasciitis.
Methods: Twenty patients with each clinical condition, clinically
and ecographically veriﬁed, were enrolled between October 2007
and March 2008 resulting in a total of eighty participants. Patients
were randomly assigned to either a study group (n = 10) or a
control group (n = 10). During 3 months all the patients received
between 20 and 30 rehabilitation sessions. In addition the study
group consumed 2.16g/d of Tendoactive™, a food supplement
containing collagen, mucopolysaccharides and vitamin C. Pain,
SF36 quality of life survey, as well as standardized functional
assessment were evaluated before and 1, 2 and 3 months after
treatment.
Results: The study group displayed a signiﬁcant pain reduction
(P<0.05) in all the subgroups except for the epicondylitis group.
Pain reduction was associated with an improvement of at least
one SF36 subscale in each subgroup (P<0.05). At the end of the
treatment a signiﬁcant improvement in the functional assessment
of the physiotherapist was reported for all the tendinopathies
(P<0.05).
Conclusions: Our results suggest that the use of Tendoactive™
for the management of tendinopathies and plantar fasciitis is safe
and effective, leading to a signiﬁcant reduction in pain and im-
proving the biomechamical properties of the joint, without adverse
effects.
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A DOSE-DEPENDENT IMPACT OF A STANDARDIZED
POWDER MADE FROM HIPS OF A ROSE SUBSPECIES
(ROSA canina) ON WOMAC PAIN SCORES IN PATIENTS
WITH OSTEOARTHRITIS OF THE HIP AND/OR KNEE
K. Winther1, A.S. Hansen1, A. Kharazmi2
1Frederiksberg Hosp., Univ. of Copenhagen, Frederiksberg,
Copenhagen, Denmark; 2RigsHosp.et, Univ. of Copenhagen,
Copenhagen, Denmark
Purpose: A ﬁxed daily dose of ﬁve grams of a standardized
powder, made from hips of a Rose subspecies (Rosa canina),
produced using a standardized methodology by Hyben Vital, Den-
mark, has signiﬁcantly lowered symptom scores in patients with
osteoarthritis and shown anti-inﬂammatory properties. The aim of
the present study was to test whether there was any indication of
a dose dependent impact on the WOMAC pain score, from the
present rose hip powder, when evaluating a group of patients all
suffering from osteoarthritis of the hip and/or knee according to the
American College of Rheumatology criteria for the classiﬁcation of
osteoarthritis.
Methods: 52 patients, mean weight 78.3 kg (range 50 -122 kg),
were randomly allocated to either 3 month treatment with ﬁve
grams daily of encapsulated standardised rose hip powder, or ﬁve
grams of placebo. There were no signiﬁcant difference regarding
weight, sex, duration of the disease, educational background or
consumption of additional pain killers, when comparing the two
groups. WOMAC questionnaires were used throughout the study
and each patients noted his/hers daily consumption of rescue
medication in a diary. Data evaluation was based on intention
to treat (ITT). To search for a possible dose-dependency of the
present treatment, a non-parametric Spearman correlation test
was applied on the active treated group as well as the placebo
group.
Results: An overall reduction in WOMAC pain, WOMAC stiffness
and ADL function was observed as a result of active treatment
when compared to placebo (p<0.05). Moreover active treatment
resulted in a reduction in the consumption of rescue medica-
tion, as compared to the consumption observed during placebo
(p<0.05). There was a signiﬁcant negative correlation between
weight and reduction in pain score in the group treated with rose
hip (correlation coefﬁcient = - 0.39, p value = 0.019) after three
weeks treatment and (correlation coefﬁcient = - 0.41, p value =
0.014) after three months treatment. No negative correlation was
observed when a similar analysis was applied on placebo treated
patients. No signiﬁcant correlation to weight was observed when
evaluating changes in WOMAC stiffness or ADL function in any of
the two groups.
Conclusions: It is suggested that the present rose hip powder
reduces WOMAC scores and the consumption of rescue medica-
tion in patients suffering from osteoarthritis of the hip and/or knee.
Further more the present powder may act dose-dependently on
pain.
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COMPARISON OF SYNOVIAL B-ENDORPHIN LEVEL IN
AVASCULAR NECROSIS, RHEUMATOID ARTHRITIS AND
OSTEOARTHRITIS OF THE FEMORAL HEAD AND KNEE
K. Tóth1, K. Wellinger1, G. Sohar1, T. Bender2, L. Mécs1
1Univ. of Szeged, Szeged, Hungary; 2Hosp.ler Brothers of St John
of God, Budapest, Hungary
Purpose: Avascular necrosis of the femoral head (AVN) is a
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pathologic process that results from interruption of blood supply
to the bone. The condition is extremely rare in healthy individuals,
although it occurs usually before the ﬁfth decade. The most
common localization of idiopathic avascular necrosis is the femoral
head, although it affects the knee as well. Pain often occurs only
at an advanced stage of the condition.
Osteoarthritis (OA) conceived as a degenerative consequence of
aging of the joint, with a well-characterized molecular pathophysiol-
ogy, whereas rheumatoid arthritis (RA) is a common, inﬂammatory
polyarthritis. The onset of RA varies from acute to insidious. The
most common site of onset is in the hands and feet. Knee joints
are also commonly affected, although it is not the initial joint.
Peripherially, or centrally released β-endorphin is an important
indicator of pain and inﬂammation. As only a limited number of
papers have been published before on the subject of the analysis
of synovial ﬂuid from hip and knee joint in different arthropathies,
we wish to reply the question whether there is a difference in
between the β-endorphin levels of patients with avascular necrosis,
osetoarthritis and rheumatoid arthritis of the hip and knee. The
role of β-endorphin in alleviation of pain has been well-described,
while there are less data of its function in synovial ﬂuid.
Methods: 87 patients (62 female, 25 male) were involved in our
study with an average age of 62 (±11.27) years. 33 patients
had avascular necrosis of stage IV, V, VI according to Steinberg’s
classiﬁcation (18 hips, 15 knees). 23 patients suffered from OA
(14 hips, 9 knees), whereas stage III-IV RA was diagnosed in 31
patients (12 hips, 19 knees) due to Steinbrocker’s classiﬁcation.
Patients with OA and RA meet the ARA requirements. We mea-
sured the β-endorphin levels of the synovial ﬂuids -harvested from
surgery- with radioimmun assay (RIA).
Results: Our experiments showed elevated level of β-endorphin in
synovial ﬂuid of patients with AVN comparing to OA and RA, how-
ever signiﬁcance was not proven due to a relatively high standard
deviation. Nevertheless β-endorphin level was signiﬁcantly higher
in RA group than among patients with OA (p=0.012). Synovial
β-endorphin level was measured lower in knee comparing to hip
joint. When examining the different joints separately in compliance
with diagnoses, we concluded that the synovial β-endorphin level
from AVN was between the values of OA and RA without signif-
icance, whereas in RA it was signiﬁcantly higher than from OA
irrespectively of the joint (p=0.03 knee, p=0.013 hip).
Conclusions: synovial β-endorphin level in patients with inﬂam-
matory autoimmune diseases (e.g. RA), comparing to the level
measured in degenerative conditions (e.g. OA). We interpret the
higher β-endorphin level in AVN than in OA with the clinically
well-known fact, that AVN is always accompanied by a synovial in-
ﬂammation. The markedly higher β-endorphin level in patients with
RA of the knee contrary to OA conﬁrms the fact that the immune
system has a strong impact on the expression of β-endorphin of
opioid receprors and ligands of peripherial sensorial neurons.
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STERNAL FRACTURE AFTER MINOR TRAUMA IN A
PATIENT WITH KYPHOSIS: A CASE REPORT
T. Nakajima, Y. Shimizu, K. Tanabe
Nishinomiya Municipal Central Hosp., Nishinomiya, Japan
Purpose: Older patients tend to suffer from osterarthritis of many
joints and osteoporosis. In such cases, several types of fractures
can easily occur. We present a case of sternal fracture after a
subtle trauma in a patient with Kyphosis. 7 days after a very slight
contact injury to her anterior chest, she suddenly experienced
severe pain. To our knowledge, there are no reports of such a
case.
Methods: We present a case of 69-year-old woman with kyposis.
One day, her anterior chest was bumped slightly. She experienced
mild discomfort in the anterior chest. She could, however, spend
daily life without a difﬁculty. 7 days after, her discomfort then
spontaneously transformed into severe pain and she visited a
hospital, but the X-ray examination revealed no rib fractures.
Nevertheless, severe pain persisted, so she visited our hospital 14
days after. On our ﬁrst examination, her anterior chest pain was
very severe. She could not move without help and a great deal of
time was required to change her body position. In our ﬁrst plain X-
ray examination, we could conﬁrm the step off fracture at the body
of the sternum and many old vertebral compression fractures in
her thoracic and lumbar spines. Fracture of the sternum was also
conﬁrmed by computed tomography, and there was no evidence of
tumoral inﬁltration and no obvious abnormality in her mediastinum.
Her bone density was examined using ultrasound, it was only
43% of the mean value for young adults. After conﬁrming chest
X-rays, electrocardiograms, Holter monitoring, echocardiograms,
pulmonary function tests, laboratory tests failed to disclose the
pathology, we made the diagnosis of sternal fracture secondary to
severe osteoporosis and kyphosis.
Results: By conservative treatment with a rib band, 70 days
after the onset, we could see the callus formation around the
fracture and her discomfort became better. But, 3 months after,
her discomfort became worse again and we conﬁrm re-fracture
at the same point. 6 months after, her pain disappeared and we
could conﬁrm callus on the X-ray. It took about a year to conﬁrm
sound bone union.
Conclusions: The sternum and ribs are usually protected from
injury by the elasticity of the costal cartilage. However, these
bones may become progressively ossiﬁed with age such that the
deforming stress due to the thoracic kyphosis may be transmitted
directly to the sternum (Sapherson, 1990). Thoracic kyphosis is
thought to enhance the potential for a sternal insufﬁciency fracture
by creating a deforming stress that exceeds the diminished elastic
resistance of the osteoporotic bone (Cooper, 1988).
Based on the clinical course of our case, sternal insufﬁciency
fracture should have been ruled out ﬁrst. In our case, re-fracture
was also seen at the same point during the treatment course.
So, in the case of the sternal fracture patients with Kyphosis and
osteoporosis, it might be better to take care of the possibility of
re-fracture.
Conclusions: 1) In patients with osteoporosis and spinal com-
pression fractures, sternal fracture must be considered if there are
any complaints of discomfort in the anterior chest. 2) A lateral
view radiograph of the sternum is important for the diagnosis of
sternal fracture. 3) It might be better to take care of the possibility
of re-fracture in the treatment of the sternal fracture patient with
kyphosis and osteopolosis.
Pain: Pathophysiology
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VALIDATION OF CLINICAL PAIN ASSESSMENT METHODS
WITH CANINE OSTEOARTHRITIS
P. Rialland1, S. Bichot1, M. Moreau1,2, B. Lussier2,
J.-P. Pelletier3, J. Martel-Pelletier3, G. Beauchamp1, D. Gauvin1,
E. Troncy1
1GREPAQ - Fac. vet. med. - Université de Montréal, St-Hyacinthe,
QC, Canada; 2GRAC - Fac. vet. med. - Université de Montréal,
St-Hyacinthe, QC, Canada; 3Osteoarthritis Res. Unit -
Notre-Dame Hosp., CR-CHUM - Université de Montréal, Montréal,
QC, Canada
Purpose: The aim of this clinical study was to evaluate the
construct and concurrent validation of chronic pain assessment
methods in dogs diagnosed with osteoarthritis (OA). Different
